Therapy for recurrent high-grade gliomas: Does continuous dose-intense temozolomide have a role?

Journal of Clinical Oncology

Volumn 28, Issue 12, 2010, Pages 1977-1979

  Wen, Patrick Y ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARMUSTINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADJUVANT THERAPY; ANAPLASTIC GLIOMA; CANCER RECURRENCE; CANCER SURVIVAL; DRUG TOLERABILITY; EDITORIAL; GLIOBLASTOMA; GLIOMA; HUMAN; METHYLATION; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; MORTALITY; NOTE; PATHOLOGY; RECURRENT DISEASE; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GLIOMA; HUMANS; RADIOTHERAPY, ADJUVANT; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951641440     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.6014     Document Type: Editorial

References (27)

1. Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain Tumors in the United States, 2000-2004. Hinsdale, IL, Central Brain Tumor Registry of the United States, 2008
2. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005 (Pubitemid 40349501)
3. Wen PY, Kesari S: Malignant gliomas in adults. N Engl J Med 359:492-507, 2008
4. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
5. Cairncross G, Berkey B, Shaw E, et al: Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group trial 9402. J Clin Oncol 24:2707-2714, 2006 (Pubitemid 46630566)
6. van den Bent MJ, Carpentier AF, Brandes AA, et al: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715-2722, 2006 (Pubitemid 46630567)
7. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4722-4740, 2009
8. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
9. Desjardins A, Reardon DA, Herndon Jr JE, et al: Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 14:7068-7073, 2008
10. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999 (Pubitemid 29368260)
11. Lamborn KR, Yung WK, Chang SM, et al: Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162-170, 2008
12. van den Bent MJ, Brandes AA, Rampling R, et al: Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 27:1268-1274, 2009
13. Wen PY, Brandes AA: Treatment of recurrent high-grade gliomas. Curr Opin Neurol 22:657-664, 2009
14. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005 (Pubitemid 40349502)
15. Weller M, Stupp R, Reifenberger G, et al: MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat Rev Neurol 6:39-51, 2010
16. van den Bent MJ, Dubbink HJ, Sanson M, et al: MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group study 26951. J Clin Oncol 27:5881-5886, 2009
17. Tolcher AW, Gerson SL, Denis L, et al: Marked inactivation of O6- alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011, 2003 (Pubitemid 36560766)
18. Hegi ME, Liu L, Herman JG, et al: Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26:4189-4199, 2008
19. Brandes A, Tosoni A, Cavallo G, et al: Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155-1160, 2006 (Pubitemid 44658477)
20. Wick A, Felsberg J, Steinbach JP, et al: Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 25:3357-3361, 2007 (Pubitemid 47325623)
21. Brada M, Gabe R, Stenning S, et al: A randomised trial of temozolomide vs PCV chemotherapy for recurrent malignant glioma (MRC BR12). 33rd meeting of the European Society for Medical Oncology, Stockholm, Sweden, September 12-16, 2008
22. Perry JR, Bélanger K, Mason WP, et al: Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 28:2051-2057, 2010
23. Tuettenberg J, Grobholz R, Korn T, et al: Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme. J Cancer Res Clin Oncol 131:31-40, 2005
24. Samuel DP, Wen PY, Kieran MW: Antiangiogenic (metronomic) chemotherapy for brain tumors: Current and future perspectives. Expert Opin Investig Drugs 18:973-983, 2009
25. Brandsma D, Stalpers L, Taal W, et al: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461, 2008 (Pubitemid 351597795)
26. Chamberlain MC, Glantz MJ, Chalmers L, et al: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81-83, 2007
27. Yip S, Miao J, Cahill DP, et al: MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15:4622-4629, 2009